Management of cancer-related anemia in patients with breast or gynecologic cancer:: New insights based on results from the European Cancer Anemia Survey

被引:47
作者
Barrett-Lee, P [1 ]
Bokemeyer, C
Gascón, P
Nortier, JWR
Schneider, M
Schrijvers, D
Van Belle, S
机构
[1] Velindre Canc Ctr, Cardiff CF14 2TL, Wales
[2] Univ Klinikum Hamburg Eppendorf, Hamburg, Germany
[3] Hosp Clin Barcelona, Barcelona, Spain
[4] Leiden Univ, Med Ctr, Leiden, Netherlands
[5] Ctr Antoine Lacassagne, F-06054 Nice, France
[6] ZNA Middleheim, Antwerp, Belgium
[7] Ghent Univ Hosp, B-9000 Ghent, Belgium
关键词
breastcancer; gynecologic cancer; ECAS; anemia;
D O I
10.1634/theoncologist.10-9-743
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The incidence, prevalence, and treatment of anemia (hemoglobin [Hb] <12 g/dl) in women with breast cancer and gynecologic cancer were evaluated using data from the European Cancer Anemia Survey (ECAS). Adult patients with newly diagnosed treated or untreated disease, persistent/recurrent disease, and disease in remission were enrolled and followed for up to six chemotherapy cycles or six evaluation points within a 6 -month period. At enrollment, 30.4% of breast cancer patients and 49.1% of gynecologic cancer patients were anemic. A significant correlation was shown between low Hb level and poor performance status ("World Health Organization criteria) at enrollment for both breast cancer and gynecologic cancer patients. In all, 62.4% of breast cancer patients and 81.4% of gynecologic cancer patients were anemic at some time during the survey. The incidence of anemia, determined in a carefully defined population, was 59.8% for breast cancer patients and 74.8% for gynecologic cancer patients. Despite the high prevalence and incidence of anemia, only 26.3% and 42.7% of patients in the respective groups received anemia treatment. In breast cancer patients, the mean Hb trigger was 10 g/dl for epoetin treatment and 8.6 g/dl for transfusion; corresponding values for gynecologic cancer patients were 10.1 g/dl and 9.1 g/dl. Logistic regression analyses in the overall ECAS population identified five factors as significant and suitable predictors of anemia: lower initial Hb, having lung or gynecologic cancer versus gastrointestinal/colorectal cancer, any other cancer versus gastrointestinal/colorectal cancer, treatment with platinum chemotherapy, and being female. The ECAS data highlight the need for greater awareness of the adverse impact of anemia on cancer patients and for optimal anemia management to ensure maximal patient quality of life.
引用
收藏
页码:743 / 757
页数:15
相关论文
共 38 条
[31]  
Portenoy R K, 1999, Oncologist, V4, P1
[32]  
Rossi A, 2004, ANTICANCER RES, V24, P317
[33]   Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients [J].
Schagen, SB ;
Muller, MJ ;
Boogerd, W ;
Rosenbrand, RM ;
van Rhijn, D ;
Rodenhuis, S ;
van Dam, FSAM .
ANNALS OF ONCOLOGY, 2002, 13 (09) :1387-1397
[34]   Once-weekly dosing of epoetin-α increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy [J].
Shasha, D ;
George, MJ ;
Harrison, LB .
CANCER, 2003, 98 (05) :1072-1079
[35]  
Van Belle S, 2004, ANN ONCOL, V15, P123
[36]   Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy [J].
van Dam, FSAM ;
Schagen, SB ;
Muller, MJ ;
Boogerd, W ;
von der Wall, E ;
Fortuyn, MED ;
Rodenhuis, S .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (03) :210-218
[37]   Quality of life in patients receiving treatment, for gynecologic malignancies: Special considerations for patient care [J].
Wenzel, L ;
Vergote, I ;
Cella, D .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2003, 83 :211-229
[38]   Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system [J].
Yellen, SB ;
Cella, DF ;
Webster, K ;
Blendowski, C ;
Kaplan, E .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1997, 13 (02) :63-74